Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Biogen Idec says FDA will allow 3 more months to review its hemophilia B drug Alprolix
Biogen Idec says FDA will allow 3 more months to review its hemophilia B drug Alprolix
Biogen Idec says FDA will allow 3 more months to review its hemophilia B drug Alprolix
Submitted by
admin
on December 2, 2013 - 10:15am
Source:
Yahoo/AP
News Tags:
Biogen Idec
FDA
hemophilia B
Alprolix
Headline:
Biogen Idec says FDA will allow 3 more months to review its hemophilia B drug Alprolix
Do Not Allow Advertisers to Use My Personal information
